Wall Street analysts see strong growth potential in 3 stocks

TipRanks, the platform that tracks analyst performance, published a short list highlighting three stocks—Tenaya Therapeutics, Immuneering and Evaxion Biotech—that Top Wall Street analysts have recently rated as buys. According to the TipRanks summary, these selections stand out because leading analysts with strong track records have maintained or reaffirmed buy recommendations and the aggregated 12‑month price targets imply substantial upside for each name.

The breakdown shows H.C. Wainwright’s Joseph Pantginis maintaining a Buy on Tenaya Therapeutics (TNYA) with TipRanks’ aggregated targets implying roughly a 283% upside. Oppenheimer’s Jay Olson remains constructive on Immuneering (IMRX), where combined analyst targets suggest around a 145% potential. Lake Street’s Thomas Flaten continues to back Evaxion Biotech (EVAX) despite a trimmed target, and TipRanks’ calculations still point to significant upside for that stock as well. These figures are drawn from TipRanks’ Top Analysts dataset and reflect consensus target-price upside rather than guaranteed outcomes.

From a market perspective, the three names are typical of early-stage biotech and therapeutic developers: they offer high growth optionality tied to clinical milestones, regulatory review and commercialization paths, but they also carry elevated event risk. Price sensitivity to trial readouts or guidance revisions is usually pronounced, which can lead to rapid intraday and multi‑week moves. For risk‑aware investors, the potential returns cited by analysts need to be balanced against binary clinical outcomes and funding/financing risks.

The broader context includes stronger investor interest in specialized biotechnology themes—such as gene and cell therapies, targeted oncology treatments, and AI‑assisted drug discovery—amid a macro environment where capital seeks above‑average growth opportunities. Nevertheless, macro factors like global liquidity, central bank policy and investor risk appetite will continue to influence sector flows and valuation multiples. Analysts typically recommend close monitoring of cash runway, trial timelines and partnership announcements as near‑term catalysts.

Looking ahead, market commentators say the next key triggers for these stocks will be clinical data releases, regulatory interactions and any changes in analyst coverage or price targets. While TipRanks’ Top Analysts highlight considerable upside, the consensus view among professionals is to treat these names as high‑conviction, high‑volatility holdings suited to investors with appropriate risk tolerance and a focus on long‑term fundamentals rather than short‑term price swings. Active monitoring and position sizing remain essential components of a prudent investment approach.